top of page

Michaël Hocquemiller


Michaël Hocquemiller is scientific director at Lysogene. He has 15 years of experience in AAV gene therapy development focused on neurodegenerative diseases. Dr. Hocquemiller has co-led the Phase 1 clinical trial in MPS IIIA, as well as designing drug candidates and pre-clinical work that have now advanced into clinical development. Before joining Lysogene, Dr. Hocquemiller worked as a research scientist at the Pasteur Institute focused on neurophysiopathology and gene therapy of Lysosomal Storage Diseases.

T2EVOLVE Logo.png
bottom of page